Hyperbaric Oxygen Therapy in Necrotizing Soft Tissue Infections: A Retrospective Study.

Necrotizing soft tissue infection is a severe life-threatening disease correlated with high mortality. Until now, therapeutic concepts include antimicrobial, intensive care and surgical interventions, as well as the application of hyperbaric oxygenation (HBO), which still has a controversial status. Evidence of the therapeutic concept of HBO is, so far, limited to positive experiences in case studies and physiological benefits in animal studies. That is why the HBO therapy method is not yet fully established. In this light, a retrospective data analysis was conducted. The analysis involved 91 intensive care patients in the Clinic for Anesthesiology and Surgical Intensive Care at the University Hospital Halle (Saale) who, because of a necrotizing soft tissue infection, were treated with HBO therapy (period of observation from 2008 to second quarter 2017). Treatment outcome was examined with regard to mortality, complications, time spent in the intensive care unit, and functional limitations. The criteria of therapy relevance, therapy management, and conclusions drawn from the treatment results were evaluated. By examining the result of combining all four categories of treatment, we aim to investigate established guidelines and their practicability. We expect treatment with HBO to have no disadvantages compared with acknowledged treatment concepts. This study considers the success of treatment as a result of complying with optimal therapy. In a contribution to establish coverage use and an inventory of hyperbaric chambers, we also aim to create a national case register, so that patients do not have to depend on long and risky transportations.

GP88/PGRN Serum Levels Are Associated with Prognosis for Oral Squamous Cell Carcinoma Patients.

Progranulin (PGRN)/GP88 is a growth factor that is expressed in a wide range of tumor tissues. The secreted form is involved in various biological processes including proliferation and inflammation. In several tumor types, the serum GP88 level is associated with a patient's prognosis; however, data for oral squamous cell carcinomas (OSCCs) have not yet been reported. We measured the serum GP88 levels in 96 OSCC patients by an enzyme immunosorbent assay (EIA) and correlated these data with clinicopathological parameters and patient outcomes. The GP88 levels in the serum of OSCC patients and healthy volunteers were comparable. In OSCC patients, the levels did not correlate with age, sex, or TNM status. In a Kaplan-Meier survival analysis, a serum GP88 level < 68 ng/mL was significantly associated with worsened survival (p = 0.0005, log-rank-test) as well as in uni- and multivariate Cox regression analyses (RR = 4.6 [1.6-12.9], p = 0.004 and RR = 4.2 [1.2-12.0], p = 0.008). This effect was predominant in OSCC patients older than 60.5 years (p = 0.027), while in younger patients no significant association between serum GP88 levels and prognosis could be observed. Altogether, lower serum GP88 levels are significantly associated with a worsened outcome for an OSCC and may be an interesting candidate for risk stratification during OSCC therapy.